1AD
Click for more information
0.00% 2.2¢ adalta limited

Ann: Corporate Presentation, page-100

  1. asx11
    3,617 Posts.
    lightbulb Created with Sketch. 389
    clock Created with Sketch.
    14/03/24
    13:21
    Post #: 72883798
    That is very different than saying the extension study added nothing new.
    It is big news considering it was increased dosage that provided NEW clinical data that was requested by potential partners. The only way you can take the position that the extension study was insignificant is if you believe Tim fabricated the whole story.
    Last edited by asx11: 14/03/24
    1AD Price at posting: 2.8¢ Sentiment: Buy Disclosure: Held
    Likes Created with Sketch. 1  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

QBE QBE records share price plunge despite doubling profits in the first half of 2024
right-arrow Created with Sketch.
RLT South Africa-based Renergen brings liquid helium facility online
right-arrow Created with Sketch.
NEWS Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market
right-arrow Created with Sketch.
NEWS Bitcoin: Current State of Play & Where to Next | Swyftx
right-arrow Created with Sketch.
TG6 TG Metals reports high grade lithium hits approaching 3% at Jaegermeister
right-arrow Created with Sketch.
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
right-arrow Created with Sketch.
watchlist Created with Sketch. Add 1AD (ASX) to my watchlist
(20min delay)
Last
2.2¢ 		Change
0.000(0.00%) 		Mkt cap ! $13.10M
Open High Low Value Volume
2.2¢ 2.2¢ 2.2¢ $0 3

Buyers (Bids)

No. Vol. Price($)
1 20000 2.3¢
 

Sellers (Offers)

Price($) Vol. No.
2.4¢ 82501 1
View Market Depth
Last trade - 10.51am 09/08/2024 (20 minute delay) ?
1AD (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.